University of Freiburg
Soluble EphB4 staunches tumor growth and angiogenesis in murine models
Published in Biotech Law Weekly, July 23rd, 2004
According to a study from Germany, "EphB receptors and their ephrinB ligands play a key role in the formation of a regular vascular system. Recent studies have also shown the involvement of Eph/ephrin interactions in malignant tumor progression and angiogenesis. We have generated soluble monomeric EphB4 (sEphB4)-expressing A375 melanoma cells to study the effect of dominant negatively acting sEphB4 on tumor growth and angiogenesis."
"Soluble EphB4-expressing A375 tumors grown subcutaneously in nude mice show dramatically reduced tumor growth compared to control tumors. The...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
Source: Biotech Law Weekly (2004-07-23)
More Articles from Biotech Law Weekly
- Alaris Medical Systems
ICU Medical announces court order in patent infringement lawsuit - Biosystemix
Data mining, predictive modeling provided for personalized medicine models - CDEX
Alpha test of ValiMed impaired clinician solution initiated - CyDex, Inc.
Hovione enters drug-development alliance for potential new products - Ethicon Endo-Surgery, Inc.
Inamed Corp. reaches settlement of patent litigation over gastric banding - Genetronics Biomedical Corp.
Two patents awarded for applications of electroporation therapy - More from this issue of Biotech Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
